459868-92-9 | Ag-014699

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$42.00	$29.00
5mg	95%	in stock	$165.00	$115.00
100mg	95%	in stock	$203.00	$142.00
250mg	95%	in stock	$320.00	$224.00
1g	95%	in stock	$1,149.00	$804.00

Description

• Catalog Number: AG19659
• Chemical Name: Ag-014699
• CAS Number: 459868-92-9
• Molecular Formula: C19H21FN3O5P
• Molecular Weight: 421.3593
• MDL Number: MFCD17010269
• SMILES: OP(=O)(O)O.CNCc1ccc(cc1)c1[nH]c2c3c1CCNC(=O)c3cc(c2)F

Computed Properties

• Complexity: 515
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 6
• Rotatable Bond Count: 3

Literature

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Lancet (London, England) 20171028

• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

  The Lancet. Oncology 20170101

• Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.

  Future oncology (London, England) 20160601

• Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

  British journal of cancer 20160329

• An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.

  BMC cancer 20160101

• Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

  Cancer discovery 20120901

• Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

  Nature medicine 20110701

• Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

  British journal of cancer 20101109

• Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100415

• Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.

  Cancer journal (Sudbury, Mass.) 20100101

• Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

  Breast cancer research : BCR 20100101

• Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081201